Two cancer treatments, medical previously only available to patients through the Cancer Drugs Fund (CDF), will now be routinely available on the NHS.
NICE has approved bosutinib for leukaemia and pemetrexed for lung cancer for routine use on the NHS because the companies that market them lowered their prices.
Previously both drugs had been available only if a person’s doctor applied through the Cancer Drugs Fund.
The discounted prices mean that both drugs are now considered value for money.
Professor Carole Longson, director of the centre for health technology evaluation at NICE, said: “It’s great to see that companies are engaging with our CDF reconsideration process in a constructive way, resulting in these positive recommendations. This is good news. As these drugs move into routine budgets, CDF funding can be freed up for other new and innovative cancer treatments.”
Read Full Article Here >>